Select a Country Careers Partnerships Investors Newsroom
PARTNERSHIPS LICENSING AREAS OF INTEREST PROCESS OVERVIEW submit opportunity
INVESTORS INVESTOR RESOURCES REPORTS & FINANCIALS STOCK Information EVENTS & PRESENTATIONS Corporate Governance
Newsroom Press Releases STATEMENTS & NOTICES Media Contacts

Resources and archives for the news media

This archive of news releases for AbbVie is intended to be a resource for the news media that covers our business, innovations, and products, and a library for anyone interested in our business. If you are a member of the news media and have questions or need additional information, please contact our Public Affairs Team.

The 5 most recent press releases appear below. Click the year link to access all the releases for that period.

Archives: Search / 2016 / 2015 / 2014

2013

Category: 

Feb 11, 2016
- Scholarship to provide financial support for exceptional students living with rheumatologic diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis or ankylosing spondylitis, as they pursue higher education goals
Feb 10, 2016
- Study meets co-primary efficacy endpoints and full results will be presented at a medical conference in 2016
Jan 29, 2016
- Reports Full-Year Adjusted EPS of $4.29, Up 29.2 Percent; GAAP EPS of $3.13
Jan 28, 2016
- The Elagolix Phase 3 uterine fibroid clinical development program includes two replicate, pivotal, six-month efficacy and safety studies followed by a six-month safety and efficacy extension study.
Jan 27, 2016
- An application is currently under review for single agent venetoclax treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including patients with the 17p deletion genetic mutation
 

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?

EXIT ABBVIE.COM

The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site.

As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to continue to this product-specific site?